Cumberland Pharmaceuticals 2025 revenue rises

Cumberland Pharmaceuticals

03/03/2026 22:12

Overview

Specialty pharmaceutical firm's Q4 2025 revenue grew 31% yr/yr to $13.7 mln

Full-year 2025 revenue rose 18% to $44.5 mln

Net loss for 2025 of $2.9 mln

Outlook

Company did not provide specific guidance for future quarters or full year 2026 in the press release

Result Drivers

INTERNATIONAL EXPANSION - Vibativ received approval in China and launched in Saudi Arabia, while ibuprofen injection was approved in Mexico, expanding Cumberland's market presence

COMMERCIAL PORTFOLIO EXPANSION - Co-commercialization of Talicia with RedHill Biopharma added to Cumberland's product offerings, targeting H. pylori infection

REIMBURSEMENT MILESTONE - Caldolor received a permanent CMS J-code, enhancing reimbursement access and supporting its use as a non-opioid pain management option

Company press release: ID:nPn3bRqFya

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Net Revenue
$44.5 mln


Analyst Coverage

The one available analyst rating on the shares is "hold"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)